Restructuring the R&D Spend of CSP- Part 2.
Clinical research infrastructure/personnel support was identified as a priority in the 2018 CSP Scholarship Task Force Report. The history of that support goes back to the early days of CSP and was mostly built around CHaRM. This initiative was clearly successful in supporting a group of CSP faculty to build and maintain a research program that furthered the mandate of the Program. In this fiscal year we are tracking towards a $125-150K CSP spend on research support through CHaRM- primarily for the support of our team of research nurse,research associate and biostatistician. However, the business model upon which CHaRM was built is no longer sustainable in our current economic environment.
In 2019 we will be restructuring that support program to try to make it more accessible to more members of the CSP and to try to better align it with the needs of the CSP. The order of priority for support will be: 1) investigator-initiated, CSP faculty-led research 2) collaborative investigator-initiated research (e.g., where a CSP faculty member is a site-investigator for a CIHR multi-site study) and 3) industry research. In all cases, support will be based on a cost-sharing arrangement/partnership where the higher the priority, the greater will be the % of the total HR cost carried by the CSP.
The process for accessing these funds has yet to be established but would involve establishing mechanisms for:
i) application for support, ii) adjudication of the requests iii) allocation of in-kind support for accessing research staff time, iv) tracking of time/effort of research staff in support of individual projects and v) demonstration of productivity by CSP recipients of that support.
We would hope to roll out a draft model for this support program in Q1 2019 and look forward to your comments and suggestions.
Publications by our Faculty this week
Abdel-Wahab M, Simonato M, Latib A, Goleski PJ, Allali A, Kaur J, Azadani AN, Horlick E, Testa L, Orvin K, Kornowski R, Kass M, Don CW, Richardt G, Webb JG, Dvir D. Clinical Valve Thrombosis After Transcatheter Aortic Valve-in-Valve Implantation. Circ Cardiovasc Interv. 2018 Nov;11(11):e006730. doi: 10.1161/CIRCINTERVENTIONS.118.006730.
Kimber DE, Kehler DS, Lytwyn J, Boreskie KF, Jung P, Alexander B, Hiebert BM, Dubiel C, Hamm NC, Stammers AN, Clarke M, Fraser C, Pedreira B, Tangri N, Hay JL, Arora RC, Duhamel TA. Pre-Operative Frailty Status Is Associated with Cardiac Rehabilitation Completion: A Retrospective Cohort Study. J Clin Med. 2018 Dec 17;7(12). pii: E560. doi: 10.3390/jcm7120560.
Zeglinski MR, Moghadam AR, Ande SR, Sheikholeslami K, Mokarram P, Sepehri Z, Rokni H, Mohtaram NK, Poorebrahim M, Masoom A, Toback M, Sareen N, Saravanan S, Jassal DS, Hashemi M, Marzban H, Schaafsma D, Singal P, Wigle JT, Czubryt MP, Akbari M, Dixon IMC, Ghavami S, Gordon JW, Dhingra S. Myocardial Cell Signaling During the Transition to Heart Failure: Cellular Signaling and Therapeutic Approaches. Compr Physiol. 2018 Dec 13;9(1):75-125. doi: 10.1002/cphy.c170053.
Konigstein M, Ben-Yehuda O, Smits PC, Love MP, Banai S, Perlman GY, Golomb M, Ozan MO, Liu M, Leon MB, Stone GW, Kandzari DE. Outcomes Among Diabetic Patients Undergoing Percutaneous Coronary Intervention With Contemporary Drug-Eluting Stents: Analysis From the BIONICS Randomized Trial. JACC Cardiovasc Interv. 2018 Dec 24;11(24):2467-2476. doi: 10.1016/j.jcin.2018.09.033.
Lieben Louis X, Raj P, Chan L, Zieroth S, Netticadan T, Wigle JT. Are the cardioprotective effects of the phytoestrogen resveratrol sex dependent? Can J Physiol Pharmacol. 2018 Dec 21. doi: 10.1139/cjpp-2018-0544. [Epub ahead of print]
